Non-opioid Pain Patches Market (2026 - 2033)

Non-opioid Pain Patches Market Trends

The global non-opioid pain patches market size was valued at USD 1.0 billion in 2025 and is projected to grow from USD 1.1 billion in 2026 to USD 1.6 billion by 2033, growing at a CAGR of 4.7% from 2026 to 2033. North America dominated the market, accounting for the largest global share of 39.8% in 2025. The alarming increase in opioid prescriptions and related overdose deaths has prompted healthcare providers and patients to seek effective non-opioid solutions. 

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Non-opioid pain patches offer localized relief without the addictive potential associated with opioids, making them highly preferred among stakeholders in the healthcare system. As the call for safer alternatives becomes more pronounced, the market for these patches is positioned for robust expansion. The growing prevalence of chronic pain is another critical driver for the non-opioid pain patches market. Approximately 50 million Americans suffer from chronic pain, highlighting the urgent need for effective pain management options. Non-opioid pain patches address various types of pain, including chronic, neuropathic, and musculoskeletal pain, thereby tackling a significant healthcare challenge. According to the European Pain Federation, in Europe, an estimated 100 million individuals experience chronic pain, representing approximately 20% of the adult population. This condition is a major contributor to disability, accounting for over 50% of sickness absences, which adversely impacts social and work life across multiple European countries.

To learn more about this report, Download Free Sample Report

In Amsterdam, recent surveys indicate that around 30% of adults report experiencing chronic pain, reflecting the broader trends observed in urban areas across Europe, where women are more frequently affected than men. As chronic pain issues continue to escalate, there is an increasing demand for effective management solutions, propelling the adoption of non-opioid pain patches. Moreover, technological advancements are poised to further accelerate market growth. Continuous research and development in transdermal delivery systems have led to the creation of more effective non-opioid pain patches.

Innovations in drug formulation and patch design have significantly enhanced both efficacy and user experience. In tandem with this, increased awareness among patients and healthcare providers regarding the benefits of non-opioid therapies fosters greater acceptance and utilization. Educational initiatives and guidelines promoting non-opioid treatments are facilitating a shift away from traditional opioid prescriptions, thus creating an environment conducive to the market’s expansion. The rise of online pharmacies and retail outlets has made non-opioid pain patches more accessible to consumers, ensuring easier purchasing options and a more robust market presence.

Market Dynamics

The non opioid pain patches market is supported by the increasing focus on safer pain management options and the growing use of topical therapies for both acute and chronic pain conditions. Healthcare providers are adopting non opioid patches to reduce systemic side effects and lower the risks associated with opioid use while maintaining effective pain relief. Demand is also supported by the aging population and the rising prevalence of musculoskeletal disorders, arthritis, and sports injuries. The market is also benefiting from advances in patch technology that improve drug delivery, adhesion, and patient comfort. In addition, increasing consumer preference for self administered pain management products and continued investment in topical analgesic research are supporting steady market growth across both prescription and over the counter segments.

Analyst Perspective

The non-opioid pain patches market is shifting from a segment primarily focused on topical pain relief to a broader pain management category, supported by improvements in transdermal drug delivery technologies and increasing demand for non-opioid therapies. The market is characterized by the presence of companies with established expertise in transdermal drug delivery, broad pain management portfolios, and strong manufacturing capabilities. Hisamitsu Pharmaceutical Co., Inc. continues to maintain a strong position through its established portfolio of topical pain patches and ongoing product development. Similarly, Teikoku Pharma, Teva Pharmaceutical Industries Ltd., Endo, Inc., and GSK plc are expanding their pain management portfolios, improving patch technologies, and increasing the availability of non-opioid treatment options across prescription and over the counter markets.

Patch Type Insights

Based on patch type, the lidocaine patches segment led the market with the largest revenue share of 35.0% in 2025, owing to their established efficacy in alleviating various pain types, including neuropathic and musculoskeletal pain. Offering localized relief with minimal systemic side effects, these patches are a preferred choice for patients and healthcare providers, further supported by their availability in both over-the-counter and prescription formulations.

Capsaicin patches are expected to grow rapidly, witnessing a CAGR of 6.7% over the forecast period. Capsaicin patches effectively manage pain from conditions such as osteoarthritis, neuropathy, and muscle injuries by depleting substance P, a neurotransmitter involved in pain signaling. With rising concerns over opioid risks, these non-invasive patches provide targeted relief with minimal side effects, enhancing patient compliance and driving their growing popularity in pain management.

Distribution Channel Insights

Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 44.3% in 2025. A variety of non-opioid pain patches are available over-the-counter, enabling customers to purchase them without prescriptions. Retail pharmacies offer an extensive range of pain management products, catering to chronic pain sufferers and responding to heightened demand for safer alternatives amid the ongoing opioid crisis, thereby enhancing sales.

To learn more about this report, Download Free Sample Report

Online pharmacies are projected to grow at the fastest CAGR of 8.1% over the forecast period. The digitization of healthcare enables patients to conveniently order non-opioid pain patches online, ensuring prompt delivery without the need for in-store visits. This benefits individuals with mobility challenges and offers a broader product selection and competitive pricing, promoting safer alternatives amid rising concerns about opioid addiction.

Regional Insights

North America dominated the non-opioid pain patches market with the largest revenue share of 39.8% in 2025. North America is increasingly aware of the opioid crisis, highlighting the necessity for safer pain management alternatives. The prevalence of chronic pain conditions drives demand, while advancements in transdermal delivery technologies enhance efficacy, positioning non-opioid patches as a favored choice, supported by clinical guidelines advocating for their adoption.

To learn more about this report, Download Free Sample Report

U.S. Non-opioid Pain Patches Market Trends

The non-opioid pain patches market in the U.S. held the largest share in the North America region in 2025. The alarming rise in opioid-related overdose statistics in the U.S. has driven healthcare providers to explore safer pain relief alternatives. Innovations such as lidocaine and diclofenac patches provide effective localized pain management, while increased accessibility through retail and online pharmacies supports consumer adoption amidst governmental initiatives to reduce opioid prescriptions.

Europe Non-opioid Pain Patches Market Trends

Europe non-opioid pain patches market held substantial market share in 2024. The rising awareness of opioid-related risks has spurred demand for non-opioid alternatives. Regulatory backing for innovative pain management, along with a focus on patient-centered care, fuels market expansion. Advancements in patch technology enhance efficacy for neuropathic and musculoskeletal pain, appealing to healthcare providers and patients.

The non-opioid pain patches market in Germany is expected to grow in the forecast period, driven by a strong healthcare system and a rising prevalence of chronic pain. The focus on innovative medical technologies fosters the adoption of advanced non-opioid patches, as healthcare professionals increasingly seek safer alternatives to opioid prescriptions.

Asia Pacific Non-opioid Pain Patches Market Trends

Asia Pacific non-opioid pain patches market is expected to register the fastest CAGR of 7.0% in the forecast period. Increasing urbanization and lifestyle changes are contributing to a rise in chronic pain conditions. Escalating healthcare expenditures and enhanced access to medical services are prompting patients to seek effective pain management solutions. The growth of e-commerce platforms facilitates access to non-opioid alternatives, driving research and development.

The non-opioid pain patches market in China is projected to grow at the fastest rate of 8.0% in the Asia Pacific market over the forecast period. The Chinese government’s initiatives to combat opioid abuse are driving a transition to safer pain management alternatives. Furthermore, advancements in pharmaceutical research have resulted in innovative non-opioid patch formulations that improve efficacy and patient compliance, while increased consumer acceptance of transdermal delivery systems fosters market growth.

Key Non-opioid Pain Patches Company Insights

Some key companies operating in the market include Acorda Therapeutics, Inc.; Teva Pharmaceutical Industries Ltd.; GSK plc; among others. The market comprises established pharmaceutical firms and emerging innovators in drug delivery systems, engaging in mergers, partnerships, and online distribution to enhance product efficacy and patient compliance.

• Teva Pharmaceutical Industries Ltd. is a global company working in generic and specialty pharmaceuticals, producing transdermal patches that deliver medications such as lidocaine and diclofenac for localized pain relief, emphasizing innovation and accessibility in non-opioid pain management solutions for chronic conditions.

• Endo, Inc. is focused on branded and generic pharmaceuticals, including non-opioid pain patches, utilizing transdermal delivery systems to manage neuropathic and musculoskeletal pain while prioritizing research and development to expand its safer, effective pain relief portfolio amidst rising opioid addiction concerns.

Key Non-opioid Pain Patches Companies

The following key companies have been profiled for this study on the non-opioid pain patches market.

• Acorda Therapeutics, Inc.

• Teva Pharmaceutical Industries Ltd.

• GSK plc

• Endo, Inc.

• Hisamitsu Pharmaceutical Co., Inc.

• IBSA Institut Biochimique SA

• Alkermes

• Teikoku Pharma

• Mylan N.V.

Recent Developments

• In October 2024, Hisamitsu Pharmaceutical announced the initiation of clinical development for HP-3150, a transdermal diclofenac sodium patch for chronic lower back pain treatment in the U.S., using its advanced drug delivery technology.

• In May 2024, Teikoku Pharma USA announced that the NMPA approved Lidoderm for treating Post Herpetic Neuralgia in China, following an exclusive licensing agreement with Link Healthcare Group since 2018.

Global Non-opioid Pain Patches Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global non-opioid pain patches market report based on patch type, distribution channel, and region:

To learn more about this report, Download Free Sample Report

• Patch Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Lidocaine Patches

  • Diclofenac Patches

  • Methyl Salicylate Patches

  • Capsaicin Patches

  • Ketoprofen Patches

  • Others (Herbal, Menthol, etc.)

• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Retail Pharmacies

  • Hospital Pharmacies

  • Online Pharmacies

  • Others (Supermarkets/Hypermarkets, DTC)

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The non-opioid pain patches market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each non-opioid pain patches segment quantified using the revenue-capture definitions in the table below.

Estimation Model

To learn more about this report, Download Free Sample Report

The global non opioid pain patches market was estimated using a commodity flow market analysis approach. Key manufacturers of non-opioid pain patches were identified, and their marketed products were benchmarked based on active ingredients, product type, pricing, distribution channels, regulatory approvals, and regional availability. Revenue generated from major prescription and over the counter pain patch products was estimated using company annual reports, investor presentations, regulatory filings, product portfolios, and industry publications. Market estimates were validated by evaluating product demand across retail pharmacies, hospital pharmacies, online pharmacies, and other distribution channels. Product availability, average selling prices, prescription trends, and over the counter sales patterns were considered to estimate regional demand. The revenues generated from key manufacturers were aggregated and adjusted by considering the market share of leading participants, product availability, geographic presence, and distribution coverage to estimate the overall market size.

Delivered Customizations

This report has been delivered with the following In-depth customizations